IP Law News

Amneal Acne Medicine Patent Loss to Galderma Partially Reversed

March 25, 2020, 5:00 PM

Amneal Pharmaceuticals LLP received a mixed ruling from the Federal Circuit Wednesday, which reversed a decision that it infringed two Galderma Laboratories LP patents while affirming that it infringed three others.

A Delaware federal court ruled that Amneal had infringed five patents related to doxycycline formulations that treat acne and rosacea owned by Galderma, Nestle Skin Health S.A., and TCD Royalty Sub LLC. The district court found Amneal infringed the patents under the doctrine of equivalents, because its product was equivalent to the patented invention even though it didn’t literally infringe.

The doctrine of equivalents requires “particularized testimony and linking...

To read the full article log in. To learn more about a subscription click here.